SJ 02
Alternative Names: Recombinant human follicle-stimulating hormone-CTP fusion protein; SJ-02Latest Information Update: 02 Feb 2026
At a glance
- Originator Shanghai Bao Pharmaceuticals
- Class Hormonal replacements; Infertility therapies; Recombinant fusion proteins
- Mechanism of Action Follicle stimulating hormone replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Infertility
Most Recent Events
- 02 Feb 2026 Launched for Infertility in China (SC)- First global launch (Shanghai Bao Pharmaceutical pipeline, February 2026)
- 10 Dec 2025 Registered for Infertility in China (SC)- First global approval
- 07 Apr 2025 Shanghai Bao Pharmaceuticals plans to submit an IND application for SJ 02 to the EMA in the first half of 2026 (Shanghai Bao Pharmaceuticals website, April 2025)